Financial Tear Sheet

Corporate Profile

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit, and to learn more about Covance Drug Development, visit

More Information

Primary IR Contact
Clarissa Willett
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Change (%) Stock is Down 0.04 (0.02%)
52 Week Low$119.38
Market Cap$16,359,865,000
Rolling EPS8.80
PE Ratio18.8739
Shares Outstanding98,500,000
Data as of 06/18/19 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $166.09 with a 52 week high of $190.00 and a 52 week low of $119.38.
Recent News & Events
06/18/19 - 8:44 a.m.
LabCorp and Mount Sinai Health System Collaborate to Establish Digital and AI-Enabled Pathology Center of Excellence
06/07/19 - 4:16 p.m.
LabCorp and QIAGEN Announce New therascreen PIK3CA Mutation Analysis Companion Diagnostic for Metastatic Breast Cancer
06/05/19 - 6:58 a.m.
LabCorp Announces New Leadership Roles
There are currently no events scheduled.
Analyst Estimates / Ratings
Mean Recommendation: 2.4

SellStrong Buy
Unable to fulfill request.
SEC Filings
Filing DateForm
06/18/198-K XBRL SEC Filing Unavailable
06/11/194 XBRL SEC Filing Unavailable
06/07/198-K XBRL SEC Filing Unavailable
06/05/198-K XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Mark S. SchroederSenior Vice President and Chief Supply Chain Officer
Sandra D. van der VaartSenior Vice President, Global General Counsel
Peter J. WilkinsonSenior Vice President and Chief Accounting Officer
Lisa J. UthgenanntChief Human Resources Officer
Brian J. CaveneyChief Medical Officer
Ownership Summary
 HoldersValue ($MM)% O/SShares
Mutual Fund2,3087,237.6446.946,506,280
Insider *2090.860.6571,844
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,876,68511.0-4,05803/31/19
BlackRock Institutional Trust Company, N.A.5,972,4746.132,22703/31/19
State Street Global Advisors (US)4,421,1554.5166,85203/31/19
Boston Partners2,737,0732.8-532,19503/31/19
Nordea Funds Oy2,080,8382.1-39,67103/31/19
Fidelity Management & Research Company1,546,6591.6691,70303/31/19
JP Morgan Asset Management1,475,2761.5-9,59103/31/19
Dimensional Fund Advisors, L.P.1,462,8791.52,66503/31/19
Geode Capital Management, L.L.C.1,435,3681.523,27503/31/19
BlackRock Investment Management, LLC1,431,7411.5180,80303/31/19